$CLDX alerted on dip & rip, Celldex Therapeutic
Post# of 22755
Posted On: 03/13/2016 12:39:12 PM
$CLDX alerted on dip & rip,
Celldex Therapeutics, Inc. to Post FY2016 Earnings of ($1.38) Per Share, Cantor Fitzgerald Forecasts (CLDX)
Posted by Noah on Mar 12th, 2016 // No Comments
Celldex Therapeutics logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Cantor Fitzgerald lifted their FY2016 earnings per share estimates for Celldex Therapeutics in a report released on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein now anticipates that the firm will post earnings per share of ($1.38) for the year, up from their prior estimate of ($1.45). Cantor Fitzgerald currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ FY2016 earnings is ($1.32) per share.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. During the same quarter in the prior year, the company posted ($0.36) EPS. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. The business’s revenue for the quarter was up 21.1% on a year-over-year basis.
Other analysts have also issued research reports about the company. Roth Capital reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday. Brean Capital reissued a “buy” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a research report on Tuesday. Leerink Partner lowered Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 7th. HC Wainwright cut their target price on Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Cowen and Company reissued an “outperform” rating and issued a $12.00 target price (down previously from $28.00) on shares of Celldex Therapeutics in a research report on Tuesday. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $20.00.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded down 3.60% during trading on Friday, reaching $3.48. The company had a trading volume of 5,001,956 shares. The firm has a 50-day moving average of $7.19 and a 200 day moving average of $12.38. The firm’s market capitalization is $343.49 million. Celldex Therapeutics has a 1-year low of $3.42 and a 1-year high of $32.82.
A hedge fund recently raised its stake in Celldex Therapeutics stock. Rhenman & Partners Asset Management boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 320,000 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the period. Rhenman & Partners Asset Management owned about 0.32% of Celldex Therapeutics worth $5,018,000 at the end of the most recent reporting period.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Celldex Therapeutics, Inc. to Post FY2016 Earnings of ($1.38) Per Share, Cantor Fitzgerald Forecasts (CLDX)
Posted by Noah on Mar 12th, 2016 // No Comments
Celldex Therapeutics logoCelldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Cantor Fitzgerald lifted their FY2016 earnings per share estimates for Celldex Therapeutics in a report released on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein now anticipates that the firm will post earnings per share of ($1.38) for the year, up from their prior estimate of ($1.45). Cantor Fitzgerald currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ FY2016 earnings is ($1.32) per share.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. During the same quarter in the prior year, the company posted ($0.36) EPS. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.80 million. The business’s revenue for the quarter was up 21.1% on a year-over-year basis.
Other analysts have also issued research reports about the company. Roth Capital reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday. Brean Capital reissued a “buy” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a research report on Tuesday. Leerink Partner lowered Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 7th. HC Wainwright cut their target price on Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Cowen and Company reissued an “outperform” rating and issued a $12.00 target price (down previously from $28.00) on shares of Celldex Therapeutics in a research report on Tuesday. Seven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $20.00.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded down 3.60% during trading on Friday, reaching $3.48. The company had a trading volume of 5,001,956 shares. The firm has a 50-day moving average of $7.19 and a 200 day moving average of $12.38. The firm’s market capitalization is $343.49 million. Celldex Therapeutics has a 1-year low of $3.42 and a 1-year high of $32.82.
A hedge fund recently raised its stake in Celldex Therapeutics stock. Rhenman & Partners Asset Management boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 320,000 shares of the biopharmaceutical company’s stock after buying an additional 25,000 shares during the period. Rhenman & Partners Asset Management owned about 0.32% of Celldex Therapeutics worth $5,018,000 at the end of the most recent reporting period.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼